Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This study will determine the safety and efficacy of moving to a second-generation manufacturing process using the CliniMACS Prodigy platform to manufacture huCART19 cells for patients with B cell Acute Lymphoblastic Leukemia (B-ALL).
Epistemonikos ID: bb215b061fc7d72ec80a25e9e93c97732e844957
First added on: May 13, 2024